PATENT CLAIM ANALYSIS

Application Number: 16170752
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "407000"]

Abstract:
Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

Claim (Index 16):
The method of  claim 12 , wherein the CCR(9)-mediated disease or condition is an inflammatory bowel disease, an allergic disease, psoriasis, atopic dermatitis, asthma, a fibrotic disease, graft rejection, a graft-v-host disease, an immune mediated food allergy, an autoimmune disease, Celiac disease, rheumatoid arthritis, thymoma, thymic carcinoma, leukemia, solid tumor, acute lymphocytic leukemia, melanoma, primary sclerosing cholangitis, hepatitis, inflammatory hepatic disease, or post-operative ileus.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.73333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13781412', '10260008', '15383788', '11453221', '10533326']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7958295025345985
- 35 USC 102 Novelty (BERT): 0.5474173915647115
- Combined Prediction Score: 0.7709882914376098
- Mean Citation Score: 314.8755920000001
- Max Citation Score: 409.82324
- Similarity Product: 281.6157559956026

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test